Parnell today announced the acquisition of Noble Pharma, a U.S.-based pharmaceutical manufacturer.
Parnell said the deal strengthens its U.S. operations and positions it to deliver products, reliable supply and an enhanced level of support to its customers and distribution partners. Noble Pharma enhances Parnell’s manufacturing capabilities, improves supply continuity, and supports continued growth across the company’s expanding product portfolio.
“Completing this acquisition marks an important milestone for Parnell,” said Parnell CEO Brad McCarthy in a statement. “Noble Pharma’s operational excellence and established U.S. manufacturing footprint perfectly complement our mission to provide consistent supply, superior quality, and exceptional service to our partners and customers.”
Noble Pharma is an FDA- and DEA-accredited, pharmaceutical manufacturer located in Menomonie, Wisconsin. Its capabilities include suspensions, liquids, tablets, boluses, powders, gels, pastes, creams, and ointments.
